Terms: = Prostate cancer AND LMO2, RBTN2, 4005, ENSG00000135363, P25791, TTG2, RBTNL1, RHOM2
12 results:
1. lmo2 upregulation due to AR deactivation in cancer-associated fibroblasts induces non-cell-autonomous growth of prostate cancer after androgen deprivation.
Chen L; Wang YY; Li D; Wang C; Wang SY; Shao SH; Zhu ZY; Zhao J; Zhang Y; Ruan Y; Han BM; Xia SJ; Jiang CY; Zhao FJ
Cancer Lett; 2021 Apr; 503():138-150. PubMed ID: 33503448
[TBL] [Abstract] [Full Text] [Related]
2. A hybrid expert approach for retrospective assessment of occupational exposures in a population-based case-control study of cancer.
Sauvé JF; Lavoué J; Nadon L; Lakhani R; Senhaji Rhazi M; Bourbonnais R; Richard H; Parent MÉ
Environ Health; 2019 Feb; 18(1):14. PubMed ID: 30770757
[TBL] [Abstract] [Full Text] [Related]
3. The impact of TRAIL on proliferation of secretory prostate cancer PC-3 cell and lmo2 gene expression.
Che Z; Li HW; Wang P; Jiang B; Li B; Zhao K; Wang SP; Gao H; Zhang MQ
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7172-7177. PubMed ID: 30468458
[TBL] [Abstract] [Full Text] [Related]
4. Expression of lmo2 in prostate Carcinoma and Adjacent Prostatic Parenchyma.
Krušlin B; Vučić M; Mašić S; Kruljac I; Lež C; Ružić B; Spajić B; Ulamec M
Acta Clin Croat; 2018 Oct; 57(Suppl 1):56-60. PubMed ID: 30457249
[TBL] [Abstract] [Full Text] [Related]
5. Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer.
Chung SD; Lin HC; Tsai MC; Kao LT; Huang CY; Chen KC
Andrology; 2016 May; 4(3):481-5. PubMed ID: 27062333
[TBL] [Abstract] [Full Text] [Related]
6. LIM domain only 2 over-expression in prostate stromal cells facilitates prostate cancer progression through paracrine of Interleukin-11.
Jiang CY; Yu JJ; Ruan Y; Wang XH; Zhao W; Wang XJ; Zhu YP; Gao Y; Hao KY; Chen L; Han BM; Xia SJ; Zhao FJ
Oncotarget; 2016 May; 7(18):26247-58. PubMed ID: 27028859
[TBL] [Abstract] [Full Text] [Related]
7. [Regulation of E-cadherin promoter activity by lmo2 impact on the progression and metastasis of prostate cancer].
Peng X; Ye Z; Gao Y
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2013 Sep; 29(5):385-9. PubMed ID: 24386807
[TBL] [Abstract] [Full Text] [Related]
8. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Paul AG; Chandran B; Sharma-Walia N
Transl Res; 2013 Aug; 162(2):77-92. PubMed ID: 23567332
[TBL] [Abstract] [Full Text] [Related]
9. Down regulation of CSL activity inhibits cell proliferation in prostate and breast cancer cells.
Yong T; Sun A; Henry MD; Meyers S; Davis JN
J Cell Biochem; 2011 Sep; 112(9):2340-51. PubMed ID: 21520243
[TBL] [Abstract] [Full Text] [Related]
10. Targeting lmo2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia.
Appert A; Nam CH; Lobato N; Priego E; Miguel RN; Blundell T; Drynan L; Sewell H; Tanaka T; Rabbitts T
Cancer Res; 2009 Jun; 69(11):4784-90. PubMed ID: 19487290
[TBL] [Abstract] [Full Text] [Related]
11. The transcription factor lmo2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities.
Gratzinger D; Zhao S; West R; Rouse RV; Vogel H; Gil EC; Levy R; Lossos IS; Natkunam Y
Am J Clin Pathol; 2009 Feb; 131(2):264-78. PubMed ID: 19141387
[TBL] [Abstract] [Full Text] [Related]
12. The significance of lmo2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract] [Full Text] [Related]
